NCT00095563 · OUTCOME

Progression-free Survival (PFS) According to RECIST

Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers · Source last updated 2017-04-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: months
Interval / dispersion: 95% Confidence Interval
Time frame: From the date of study enrolment to disease progression, death or last contact, or last tumor assessment before the start of further anti-tumor therapy, assessed up to 5 years

Analysis population: 36 assessable participants, 19 with ACC and 17 with non-ACC.

Groups in this outcome

Treatment (Lapatinib Ditosylate)

Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. lapatinib ditosylate: Given orally laboratory biomarker analysis: Correlative studies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Treatment (Lapatinib Ditosylate)	36

Reported measurements

ACC

Analysis denominator · Participants

Group	Source count
Treatment (Lapatinib Ditosylate)	19

Values in months · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Treatment (Lapatinib Ditosylate)	3.6	Not reported	3.1	12.4	Not reported

Non-ACC

Analysis denominator · Participants

Group	Source count
Treatment (Lapatinib Ditosylate)	17

Values in months · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Treatment (Lapatinib Ditosylate)	2.1	Not reported	1.6	9.2	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
3.1
upper Limit
12.4
value
3.6
denoms
counts
group Id
OG000
value
19
units
Participants
title
ACC
categories
measurements
group Id
OG000
lower Limit
1.6
upper Limit
9.2
value
2.1
denoms
counts
group Id
OG000
value
17
units
Participants
title
Non-ACC

denoms

counts
group Id
OG000
value
36
units
Participants

dispersion Type

95% Confidence Interval

groups

description
Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. lapatinib ditosylate: Given orally laboratory biomarker analysis: Correlative studies
id
OG000
title
Treatment (Lapatinib Ditosylate)

param Type

MEDIAN

population Description

36 assessable participants, 19 with ACC and 17 with non-ACC.

reporting Status

POSTED

time Frame

From the date of study enrolment to disease progression, death or last contact, or last tumor assessment before the start of further anti-tumor therapy, assessed up to 5 years

title

Progression-free Survival (PFS) According to RECIST

type

SECONDARY

unit Of Measure

months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice